Literature DB >> 32297722

Consensus statement on the use of clozapine during the COVID-19 pandemic.

Dan Siskind1, William G Honer1, Scott Clark1, Christoph U Correll1, Alkomiet Hasan1, Oliver Howes1, John M Kane1, Deanna L Kelly1, Robert Laitman1, Jimmy Lee1, James H MacCabe1, Nick Myles1, Jimmi Nielsen1, Peter F Schulte1, David Taylor1, Helene Verdoux1, Amanda Wheeler1, Oliver Freudenreich1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32297722      PMCID： PMC7828973          DOI： 10.1503/jpn.200061

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN： 1180-4882            Impact factor:   6.186


× No keyword cloud information.
  11 in total

Review 1.  The impact of clozapine on hospital use: a systematic review and meta-analysis.

Authors:  R Land; D Siskind; P McArdle; S Kisely; K Winckel; S A Hollingworth
Journal:  Acta Psychiatr Scand       Date:  2017-02-03       Impact factor: 6.392

Review 2.  Hematologic consequences of viral infections.

Authors:  B Baranski; N Young
Journal:  Hematol Oncol Clin North Am       Date:  1987-06       Impact factor: 3.722

3.  Pneumonia may be more frequent and have more fatal outcomes with clozapine than with other second-generation antipsychotics.

Authors:  Jose de Leon; Emilio J Sanz; G Niklas Norén; Carlos De Las Cuevas
Journal:  World Psychiatry       Date:  2020-02       Impact factor: 49.548

4.  Meta-analysis examining the epidemiology of clozapine-associated neutropenia.

Authors:  N Myles; H Myles; S Xia; M Large; S Kisely; C Galletly; R Bird; D Siskind
Journal:  Acta Psychiatr Scand       Date:  2018-05-21       Impact factor: 6.392

5.  Individual changes in clozapine levels after smoking cessation: results and a predictive model.

Authors:  J M Meyer
Journal:  J Clin Psychopharmacol       Date:  2001-12       Impact factor: 3.153

Review 6.  Elevated clozapine levels associated with infection: A systematic review.

Authors:  Scott R Clark; Nicola S Warren; Gajin Kim; David Jankowiak; Klaus Oliver Schubert; Steve Kisely; Tori Forrester; Bernhard T Baune; Dan J Siskind
Journal:  Schizophr Res       Date:  2017-04-06       Impact factor: 4.939

Review 7.  Worldwide Differences in Regulations of Clozapine Use.

Authors:  Jimmi Nielsen; Corina Young; Petru Ifteni; Taishiro Kishimoto; Yu-Tao Xiang; Peter F J Schulte; Christoph U Correll; David Taylor
Journal:  CNS Drugs       Date:  2016-02       Impact factor: 5.749

8.  Clozapine-induced agranulocytosis: Evidence for an immune-mediated mechanism from a patient-specific in-vitro approach.

Authors:  Francesca Regen; Irmelin Herzog; Eric Hahn; Claudia Ruehl; Nathalie Le Bret; Michael Dettling; Isabella Heuser; Julian Hellmann-Regen
Journal:  Toxicol Appl Pharmacol       Date:  2016-12-06       Impact factor: 4.219

9.  Clozapine and Long-Term Mortality Risk in Patients With Schizophrenia: A Systematic Review and Meta-analysis of Studies Lasting 1.1-12.5 Years.

Authors:  Jentien M Vermeulen; Geeske van Rooijen; Marita P J van de Kerkhof; Arjen L Sutterland; Christoph U Correll; Lieuwe de Haan
Journal:  Schizophr Bull       Date:  2019-03-07       Impact factor: 9.306

Review 10.  Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis.

Authors:  Dan Siskind; Lara McCartney; Romi Goldschlager; Steve Kisely
Journal:  Br J Psychiatry       Date:  2016-07-07       Impact factor: 9.319
View more
  23 in total

1.  A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia.

Authors:  C U Correll; Ofer Agid; Benedicto Crespo-Facorro; Andrea de Bartolomeis; Andrea Fagiolini; Niko Seppälä; Oliver D Howes
Journal:  CNS Drugs       Date:  2022-06-27       Impact factor: 6.497

Review 2.  [Informations on psychotropics and their adaptations for patients suffering from mental disorders in France during the SARS-CoV-2 epidemic].

Authors:  H Javelot; P-M Llorca; D Drapier; E Fakra; C Hingray; G Meyer; S Dizet; A Egron; C Straczek; M Roser; M Masson; R Gaillard; P Fossati; E Haffen
Journal:  Encephale       Date:  2020-05-04       Impact factor: 1.291

3.  Clozapine Metabolism is Associated With Absolute Neutrophil Count in Individuals With Treatment-Resistant Schizophrenia.

Authors:  Isabella R Willcocks; Sophie E Legge; Mariana Nalmpanti; Lucy Mazzeo; Adrian King; John Jansen; Marinka Helthuis; Michael J Owen; Michael C O'Donovan; James T R Walters; Antonio F Pardiñas
Journal:  Front Pharmacol       Date:  2021-04-16       Impact factor: 5.810

4.  Mental Health Effects of COVID-19 Pandemia: A Review of Clinical and Psychological Traits.

Authors:  Konstantinos Kontoangelos; Marina Economou; Charalambos Papageorgiou
Journal:  Psychiatry Investig       Date:  2020-06-15       Impact factor: 2.505

Review 5.  How mental health care should change as a consequence of the COVID-19 pandemic.

Authors:  Carmen Moreno; Til Wykes; Silvana Galderisi; Merete Nordentoft; Nicolas Crossley; Nev Jones; Mary Cannon; Christoph U Correll; Louise Byrne; Sarah Carr; Eric Y H Chen; Philip Gorwood; Sonia Johnson; Hilkka Kärkkäinen; John H Krystal; Jimmy Lee; Jeffrey Lieberman; Carlos López-Jaramillo; Miia Männikkö; Michael R Phillips; Hiroyuki Uchida; Eduard Vieta; Antonio Vita; Celso Arango
Journal:  Lancet Psychiatry       Date:  2020-07-16       Impact factor: 27.083

Review 6.  Clozapine: An Updated Overview of Pharmacogenetic Biomarkers, Risks, and Safety-Particularities in the Context of COVID-19.

Authors:  Ana Miruna Dragoi; Ioana Radulescu; Bogdana Adriana Năsui; Anca Lucia Pop; Valentin Nicolae Varlas; Simona Trifu
Journal:  Brain Sci       Date:  2020-11-11

Review 7.  How Does COVID-19 Affect the Neurobiology of Suicide?

Authors:  I Conejero; B Nobile; E Olié; Ph Courtet
Journal:  Curr Psychiatry Rep       Date:  2021-03-03       Impact factor: 5.285

8.  Clozapine prescribing and safety during COVID-19.

Authors:  Ovais Wadoo; Mustafa Abdul Karim; Yassin ElTorki; Sadaf Riaz; Javed Latoo; Majid Alabdulla
Journal:  Asian J Psychiatr       Date:  2021-04-10

9.  Clozapine-related immunodeficiency: Implications for Parkinson's disease psychosis in the context of the COVID-19 pandemic.

Authors:  M Aubignat
Journal:  Rev Neurol (Paris)       Date:  2021-06-24       Impact factor: 2.607

10.  Mental health during COVID-19 in Qatar.

Authors:  Ovais Wadoo; Javed Latoo; Shuja Mohd Reagu; Raed Ahmad Assi Amro; Naseer Ahmad Masoodi; Majid Alabdulla
Journal:  Gen Psychiatr       Date:  2020-10-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.